Overview

The United States Sleep & Snoring Device Market was valued at USD 2.08 billion in 2025 and is projected to reach USD 3.629 billion by 2034, growing at a CAGR of 6.43% during the forecast period (2026-2034). The market is driven by rising sleep-disorder prevalence and growing demand for sleep apnea and snoring treatment devices. The market is shifting from standard, one-size-fits-all therapeutic devices toward AI-enabled, personalized comfort and adherence technology that uses machine learning to tailor pressure settings and mask fit to individual patient needs, reflecting the wider move across the US medical device industry toward connected, data-driven chronic disease management. The market's competitive structure has been reshaped by Philips Respironics' continued absence from new CPAP and BiPAP device sales in the United States under a 2024 FDA consent decree, with industry analysts estimating a plausible re-entry window of 2026 to 2028, a dynamic that continues to benefit remaining major suppliers. By region, the South held the largest share of the market in 2025, supported by the region's high prevalence of obesity-related sleep apnea and large patient population. The West is expected to grow at the fastest CAGR during the forecast period, aided by strong healthcare technology adoption and rising diagnostic awareness across the region's major metropolitan markets.

Market Size & Share

Market Dynamics

KEY MARKET TREND:

AI-Personalized Therapy and Comfort-Focused Design Emerging as a Transformational Trend

• Manufacturers are increasingly integrating artificial intelligence and machine learning into CPAP therapy devices to personalize comfort settings and pressure delivery based on individual patient data, improving long-term treatment adherence.
• Demand for custom-fitted, personalized sleep apnea masks continues to expand as manufacturers address common patient complaints around comfort and fit that have historically limited therapy compliance.
• Growing integration of sleep apnea devices with consumer technology, including smartphone companion apps and cloud-connected data platforms, continues to enhance patient engagement and enable remote monitoring by healthcare providers.
• Continued application of large-scale, real-world sleep data sets to train personalization algorithms reflects a broader industry shift toward evidence-based, individualized therapy calibration rather than generic default settings.

KEY MARKET DRIVER

Rising Sleep Apnea Prevalence and Altered Competitive Dynamics is the Key Driver

• The growing prevalence of obstructive sleep apnea, driven in part by rising obesity rates, continues to expand the US patient population eligible for therapeutic and diagnostic sleep apnea devices.
• Increasing awareness of the health risks associated with untreated sleep apnea, including cardiovascular disease and type 2 diabetes, continues to drive higher diagnosis rates and corresponding device demand.
• Continued growth in home-based sleep testing and CPAP therapy adoption continues to support demand as healthcare delivery shifts away from hospital-based diagnostic settings toward more accessible home care models.
• The United States Sleep & Snoring Device Market is driven by the high prevalence of sleep apnea, with an estimated 83.7 million U.S. adults aged 20 and above affected by OSA in 2024, representing 32.4% of the adult population and creating substantial demand for sleep apnea and snoring management devices.

KEY MARKET OPPORTUNITY

Adherence-Focused Innovation and Alternative Therapy Expansion Create Significant Market Opportunity

• Expansion of AI-personalized therapy platforms offers manufacturers an opportunity to differentiate on patient adherence outcomes, a key metric increasingly tied to payer reimbursement and long-term device replacement demand.
• Growing adoption of alternative, non-mask therapy options such as hypoglossal nerve stimulation offers manufacturers an opportunity to capture patients who are unable to tolerate traditional CPAP therapy.
• Continued expansion of direct-to-consumer and online distribution for accessories and replacement supplies offers manufacturers an opportunity to build recurring revenue streams beyond initial device sales.
• Nyxoah received FDA approval in 2025 for its Genio hypoglossal nerve stimulation system for a subset of patients with moderate to severe obstructive sleep apnea, expanding available treatment options beyond traditional airway pressure therapy.

United States Sleep & Snoring Device Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Product Type

Therapeutic devices held the largest market share in 2025, supported by the established role of positive airway pressure therapy in managing obstructive sleep apnea and its ability to provide consistent airway support during sleep. The segment benefits from the broad application of CPAP, BiPAP, and other airway-pressure systems across different levels of OSA severity, while their suitability for long-term treatment, integration with monitoring and adherence-support features, and availability for both clinical and home-based care continue to strengthen their position within the sleep and snoring device market.

Sleep apnea masks are projected to grow at the fastest CAGR during the forecast period, driven by continued innovation in customized and comfort-focused mask designs that improve facial fit, reduce air leakage and pressure-related discomfort, minimize irritation and other mask-related side effects, and provide patients with a more personalized and tolerable CPAP experience, thereby addressing key barriers to consistent long-term therapy use.

Product Type categories include

               ·           Therapeutic Devices (Dominating Segment)

               ·           Sleep Apnea Masks (Highest CAGR Segment)

               ·           Diagnostic Devices

Analysis by Device Type

Continuous positive airway pressure devices held the largest market share in 2025, supported by their established role as a standard treatment for obstructive sleep apnea and their widespread use for maintaining airway patency during sleep. Their proven therapeutic role, established treatment protocols, suitability for long-term management, and compatibility with different mask and delivery configurations continue to reinforce CPAP devices as a core component of OSA treatment across clinical and home-care settings.

Auto-adjusting positive airway pressure devices are projected to grow at the fastest CAGR during the forecast period, driven by their ability to automatically modify pressure levels in response to changing breathing conditions and airway requirements. Their capacity to respond to variations in airflow, airway resistance, body position, and other factors during sleep provides greater treatment flexibility, while the option for home-based initiation and personalized pressure delivery strengthens their appeal for patients and clinicians seeking adaptable approaches to ongoing OSA management.

Device Type categories include

               ·           CPAP (Dominating Segment)

               ·           Auto-Adjusting Positive Airway Pressure (Highest CAGR Segment)

               ·           BiPAP

               ·           Oral Appliances

Analysis by End-User

Hospitals held the largest market share in 2025, supported by their continued importance in comprehensive sleep apnea evaluation, polysomnography, clinical diagnosis, treatment initiation, and therapeutic device selection and fitting. Their ability to provide supervised diagnostic testing and coordinated clinical care makes hospital-based settings an important point of care for patients requiring detailed assessment and treatment planning.

Home care settings are projected to grow at the fastest CAGR during the forecast period, driven by the increasing adoption of home-based sleep apnea testing and the growing shift toward managing CPAP therapy outside traditional clinical environments. The convenience of conducting diagnostic assessments at home, combined with greater access to home-use therapeutic equipment, remote monitoring, follow-up support, and telemedicine-enabled care, is expanding the role of home settings throughout the diagnosis and ongoing management of sleep apnea.

End-User categories include

               ·           Hospitals (Dominating Segment)

               ·           Home Care Settings (Highest CAGR Segment)

Analysis by Distribution Channel

Retail pharmacies and durable medical equipment providers held the largest market share in 2025, supported by their established role in supplying prescribed sleep apnea devices, replacement components, and recurring therapy supplies. Their accessibility, product availability, patient support services, and ability to provide essential equipment and replacement accessories continue to reinforce their importance as a primary distribution channel for sleep apnea treatment.

Online is projected to grow at the fastest CAGR during the forecast period, driven by the increasing availability of sleep apnea devices and replacement accessories through e-commerce platforms. The convenience of home delivery, broader product selection, easy access to compatible masks, filters, tubing, and other consumable components, and the growing preference for purchasing recurring therapy supplies online are expected to strengthen the segment's growth.

Distribution Channel categories include

               ·           Retail Pharmacies (Dominating Segment)

               ·           Online (Highest CAGR Segment)

By Region

United States Sleep & Snoring Device Market Regional Analysis

United States Sleep & Snoring Device Market Share 2025, by Region

North America

XX%

South America

XX%

Europe

XX%

Middle East Africa

XX%

Asia Pacific

XX%

Regional Analysis

The South held the largest market share in 2025, supported by the region’s comparatively high burden of obesity and its associated impact on sleep apnea prevalence, along with a broad and diverse patient base distributed across established urban and metropolitan healthcare markets. The combination of greater disease burden, increasing awareness and diagnosis of sleep-related breathing disorders, and continued access to diagnostic and treatment services strengthens the region’s underlying demand for sleep apnea management solutions. In addition, the presence of a substantial diagnosed patient population supports recurring demand for therapeutic devices, replacement components, and essential accessories, reinforcing the South’s position as a major regional market.

The West is projected to grow at the fastest CAGR during the forecast period, driven by strong adoption of advanced healthcare technologies and increasing awareness of sleep-related breathing disorders across the region’s major metropolitan markets. Growing familiarity with digital health solutions, connected monitoring technologies, and technology-enabled approaches to sleep assessment is encouraging greater acceptance of modern sleep apnea management solutions. The region’s advanced healthcare infrastructure, expanding emphasis on early diagnosis, and growing preference for personalized and data-driven care are further supporting the adoption of AI-enabled, connected, and remotely monitored sleep apnea devices, strengthening the West’s growth prospects throughout the forecast period.

Regions Covered

               ·           South (Dominating Region)

               ·           West (Fastest-Growing Region)

               ·           Midwest

               ·           Northeast

Market Share

The United States Sleep & Snoring Device Market is consolidated, with ResMed holding a leading position that has been further reinforced by Philips Respironics' continued absence from new US device sales, alongside Fisher & Paykel Healthcare, which has expanded its mask and device adoption during this period of altered competitive dynamics. Specialized diagnostic equipment manufacturers including Natus Medical and Compumedics maintain strong positions in polysomnography and home sleep testing, while emerging companies such as Nyxoah are introducing alternative, non-mask therapy technologies. Key success factors include FDA regulatory compliance track record, patient adherence-focused product design, and breadth of durable medical equipment distribution relationships. Leading suppliers are prioritizing continued investment in AI-personalized therapy platforms, custom-fitted mask innovation, and expansion into alternative therapy technologies for CPAP-intolerant patients.

Key Players

               ·           ResMed Inc. (US)

               ·           Koninklijke Philips N.V. (Netherlands)

               ·           Fisher & Paykel Healthcare Corporation Limited (New Zealand)

               ·           Natus Medical Incorporated (US)

               ·           Compumedics Limited (Australia)

               ·           SomnoMed Limited (Australia)

               ·           Becton, Dickinson and Company (CareFusion) (US)

               ·           Nyxoah S.A. (Belgium)

               ·           ProSomnus Sleep Technologies, Inc. (US)

               ·           Löwenstein Medical Technology GmbH + Co. KG (Germany)

               ·           Drive DeVilbiss Healthcare (US)

               ·           BMC Medical Co., Ltd. (China)

               ·           Apex Medical Corp. (Taiwan)

               ·           Vyaire Medical, Inc. (US)

               ·           Circadiance, LLC (US)

Recent Market Developments

• April 2025: ResMed expanded its U.S. sleep-apnea portfolio by making the FDA-cleared NightOwl home sleep apnea test available nationwide, supporting more accessible at-home OSA diagnosis and strengthening demand across the U.S. sleep & snoring devices market.
• December 2025: ResMed received U.S. FDA clearance for Smart Comfort, an AI-enabled device that personalizes CPAP comfort settings, supporting improved therapy adherence and strengthening innovation in the U.S. sleep & snoring devices market.
• May 2026: ResMed partnered with OURA to expand access to sleep-health education and care pathways in the U.S., helping users identify potential nighttime breathing issues and connect with appropriate sleep-care resources, supporting growth in the U.S. sleep & snoring devices market.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is a sleep and snoring device?

2

What is the CAGR of the United States Sleep & Snoring Device Market?

3

Which product type leads the United States Sleep & Snoring Device Market?

4

Which device type dominates the market?

5

Which end-user segment is growing fastest?

6

What are the latest trends in the United States Sleep & Snoring Device Market?

7

Who are the leading sleep and snoring device companies in the United States?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates